3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Venous Thromboembolism
3
Neoplasms
3
Venous Thrombosis
2
Thromboembolism
2
Pulmonary Embolism
2
Multiple Myeloma
2
Lymphoma
2
Lung Neoplasms
2
Colorectal Neoplasms
2
Vascular Diseases
1
Urogenital Neoplasms
1
Prostatic Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Non-Small-Cell Lung
1
Breast Neoplasms
1
Brain Neoplasms
1
Interventions
Fluorouracil
4
Oxaliplatin
3
Leucovorin
3
Irinotecan
3
Bevacizumab
3
5,10-methylenetetrahydrofolic acid
3
Colonoscopy
2
Capecitabine
2
Bisacodyl
2
trametinib
1
spartalizumab
1
pralsetinib
1
nazartinib
1
napabucasin
1
guadecitabine
1
canakinumab
1
Ursodeoxycholic Acid
1
Tinzaparin
1
Suction
1
Simvastatin
1
Radiotherapy
1
Polyethylene Glycols
1
Pemetrexed
1
Oviposition
1
Ocoxin
1
Mass Screening
1
Levoleucovorin
1
Drainage
1
Cyclophosphamide
1
Cetuximab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Intestinal Neoplasms
×
Tinzaparin
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled